ASCVD risk – Medxy AI

Phase 1 and 1b/2a trials demonstrate that MAR001, an ANGPTL4 inhibitory antibody, safely reduces triglycerides and remnant cholesterol, supporting its potential to lower ASCVD risk beyond current therapies.

Enhancing Cognitive Function in Older Adults with Type 2 Diabetes: The Superior Effects of Tai Chi in a Mobile Health Trial
Tai Chi and Cognitive Enhancement in Older Adults With Type 2 Diabetes Mellitus: Evidence From Randomized Controlled Trials Using Wearable Technology in mHealth Models
Add-on Probiotics for Inflammatory Depression: Insights from a Double-Blind Randomized Placebo-Controlled Trial
Enhancing Vagal Nerve Function with Multi-Species Probiotics: A Promising Therapeutic Avenue for Major Depression
Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging AI artificial intelligence blood pressure breast cancer cardiovascular health cardiovascular risk clinical trial COVID-19 depression diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity mental health metformin Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng Trí tuệ nhân tạo type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Scroll to Top